|
MECOM expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.340172748447E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.13670250568543E-11 |
| Normal-vs-Stage2 |
8.606000E-04 |
| Normal-vs-Stage3 |
6.5010000049881E-08 |
| Normal-vs-Stage4 |
4.62590000005481E-06 |
| Stage1-vs-Stage2 |
4.961600E-01 |
| Stage1-vs-Stage3 |
6.938200E-01 |
| Stage1-vs-Stage4 |
1.439640E-01 |
| Stage2-vs-Stage3 |
6.640400E-01 |
| Stage2-vs-Stage4 |
7.221600E-01 |
| Stage3-vs-Stage4 |
2.963400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.14980280641453E-11 |
| Normal-vs-AfricanAmerican |
1.401300E-03 |
| Normal-vs-Asian |
9.75670000014084E-07 |
| Caucasian-vs-AfricanAmerican |
5.495800E-02 |
| Caucasian-vs-Asian |
2.372000E-02 |
| AfricanAmerican-vs-Asian |
4.769800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.34069999546682E-09 |
| Normal-vs-Female |
1.25059962385876E-11 |
| Male-vs-Female |
6.180000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.20050003271643E-09 |
| Normal-vs-Age(41-60Yrs) |
1.80260029125634E-10 |
| Normal-vs-Age(61-80Yrs) |
6.19709999982732E-07 |
| Normal-vs-Age(81-100Yrs) |
5.817600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.961000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.738200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.560300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.082000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.473800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.655190E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.351600E-01 |
| Classical-VS-Follicular |
4.420300E-03 |
| Classical-VS-Other |
1.257540E-02 |
| Classical-VS-Normal |
1.626032641866E-12 |
| Tall-VS-Follicular |
2.633000E-01 |
| Tall-VS-Other |
1.127380E-01 |
| Tall-VS-Normal |
3.043800E-04 |
| Follicular-VS-Other |
3.878000E-01 |
| Follicular-VS-Normal |
5.406000E-04 |
| Other-VS-Normal |
5.011600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.46989997530068E-09 |
| Normal-vs-N1 |
9.82230000001749E-07 |
| N0-vs-N1 |
3.771900E-02 |
|
|
